本文言語 | 英語 |
---|---|
ページ(範囲) | 3230-3233 |
ページ数 | 4 |
ジャーナル | Blood Advances |
巻 | 6 |
号 | 11 |
DOI | |
出版ステータス | 出版済み - 14-06-2022 |
All Science Journal Classification (ASJC) codes
- 血液学
UN SDG
この成果は、次の持続可能な開発目標に貢献しています
文献へのアクセス
他のファイルとリンク
引用スタイル
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Blood Advances, Vol. 6, No. 11, 14.06.2022, p. 3230-3233.
研究成果: ジャーナルへの寄稿 › Letter › 査読
TY - JOUR
T1 - CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma
AU - Okamoto, Akinao
AU - Fujigaki, Hidetsugu
AU - Iriyama, Chisako
AU - Goto, Naoe
AU - Yamamoto, Hideyuki
AU - Mihara, Keichiro
AU - Inaguma, Yoko
AU - Miura, Yasuo
AU - Furukawa, Katsuya
AU - Yamamoto, Yukiya
AU - Akatsuka, Yoshiki
AU - Kasahara, Senji
AU - Miyao, Kotaro
AU - Tokuda, Masutaka
AU - Sato, Seiko
AU - Mizutani, Yuki
AU - Osawa, Michiko
AU - Hattori, Keiko
AU - Iba, Sachiko
AU - Kajiya, Ryoko
AU - Okamoto, Masataka
AU - Saito, Kuniaki
AU - Tomita, Akihiro
N1 - Funding Information: funding from Takara Bio and lecture fees from Janssen Pharmaceutical, Sanofi, and CSL Behring. Y.A. has received honoraria from Cel-gene, Takeda Pharmaceutical, Kyowa Kirin, Teijin Pharma, Novartis Japan, Astra Zeneca, Sanofi, Shire Japan, Chugai Pharmaceutical, Janssen Pharmaceutical, and Bristol Myers Squibb; has served in as an advisor to Takeda Bio; and has received research funding from SRL and Bristol Myers Squibb. K. Miyao has received lecture fees from Novartis Japan, Kyowa Kirin, Nippon Shinyaku, Takeda Pharmaceutical, Eisai, Janssen Pharmaceutical, Bristol Myers Squibb, Cel-gene, Ono Pharmaceutical, and Otsuka Pharmaceutical. K.S. belongs to an endowed department sponsored by FUJIFILIM Wako Pure Chemical Corporation. A.T. has received research funding from Chugai Pharmaceutical, Astellas Pharma, Eisai, Otsuka Pharmaceutical, Ono Pharmaceutical, Kyowa Kirin, Shionogi, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Takeda Pharmaceutical, Teijin, Nippon Shinyaku, Nihon Pharmaceutical, Pfizer Japan, Mochida Pharmaceutical, Yakult Honsha, and Perseus Proteomics; and lecture fees from Chugai Pharmaceutical, Kyowa Kirin, Eisai, Takeda Pharmaceutical, Astellas Pharma, Nippon Shinyaku, Janssen Pharmaceutical, Zenyaku Kogyo, AbbVie GK, Bristol Myers Squibb, and SymBio Pharmaceutical.
PY - 2022/6/14
Y1 - 2022/6/14
UR - http://www.scopus.com/inward/record.url?scp=85130793919&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130793919&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2021006302
DO - 10.1182/bloodadvances.2021006302
M3 - Letter
C2 - 35026843
AN - SCOPUS:85130793919
SN - 2473-9529
VL - 6
SP - 3230
EP - 3233
JO - Blood Advances
JF - Blood Advances
IS - 11
ER -